Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Update

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 56,514 shares, an increase of 172.7% from the August 15th total of 20,724 shares. Approximately 1.2% of the shares of the company are sold short. Based on an average daily trading volume, of 950,731 shares, the short-interest ratio is presently 0.1 days.

Evaxion A/S Stock Performance

Evaxion A/S stock opened at $3.07 on Tuesday. The company’s 50-day moving average price is $3.08 and its 200-day moving average price is $3.54. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.69. The company has a market cap of $25.60 million, a PE ratio of -2.54 and a beta of 0.26. Evaxion A/S has a twelve month low of $2.77 and a twelve month high of $12.15.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Investors Weigh In On Evaxion A/S

Several institutional investors have recently made changes to their positions in EVAX. Rathbones Group PLC bought a new position in Evaxion A/S during the 1st quarter valued at about $170,000. Renaissance Technologies LLC purchased a new position in shares of Evaxion A/S during the first quarter valued at approximately $146,000. Finally, Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Evaxion A/S during the first quarter valued at approximately $112,000. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.